[{"id":"2cd0bb28-fe10-4b8b-9287-18ad8a95d0b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990233","created_at":"2025-06-28T13:37:59.942Z","updated_at":"2025-06-28T13:37:59.942Z","phase":"Phase 1","brief_title":"A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03990233","lead_sponsor":"OSE Immunotherapeutics","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-06-26"},{"id":"89ce58f7-0046-45a6-9589-68bba343777d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249426","created_at":"2024-03-27T13:37:18.528Z","updated_at":"2025-02-25T14:16:43.633Z","phase":"Phase 1","brief_title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","source_id_and_acronym":"NCT05249426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-18"},{"id":"8684fe35-4cc2-47ff-bb79-45f67ae9a6b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068102","created_at":"2021-10-05T20:00:16.409Z","updated_at":"2024-07-02T16:35:00.041Z","phase":"Phase 1","brief_title":"A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab","source_id_and_acronym":"NCT05068102","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063 • BI 770371"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 03/21/2025","study_completion_date":" 03/21/2025","last_update_posted":"2024-05-30"},{"id":"97ed81de-4986-4ca6-9f9a-c890f0cf6354","acronym":"","url":"https://clinicaltrials.gov/study/NCT05765851","created_at":"2023-03-13T15:02:22.751Z","updated_at":"2025-02-25T15:00:49.420Z","phase":"Phase 1","brief_title":"A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05765851","lead_sponsor":"Daiichi Sankyo","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 mutation • HER-2 expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • DS-1103"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-30"},{"id":"037526fa-c1e8-4a48-8938-114bba08f003","acronym":"CC-95251-ST-001","url":"https://clinicaltrials.gov/study/NCT03783403","created_at":"2021-07-05T17:19:06.404Z","updated_at":"2024-07-02T16:35:27.351Z","phase":"Phase 1","brief_title":"A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers","source_id_and_acronym":"NCT03783403 - CC-95251-ST-001","lead_sponsor":"Celgene","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Rituxan (rituximab) • anzurstobart (BMS-986351)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 06/20/2024","primary_completion_date":" 06/20/2024","study_txt":" Completion: 08/23/2024","study_completion_date":" 08/23/2024","last_update_posted":"2023-12-01"},{"id":"592759fa-15ae-4b9c-8238-0dda975b7c5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04980690","created_at":"2021-07-28T19:52:34.744Z","updated_at":"2024-07-02T16:35:53.531Z","phase":"Phase 1/2","brief_title":"Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors","source_id_and_acronym":"NCT04980690","lead_sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBC0966"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-03-10"},{"id":"1fd7db54-93ac-41e4-bc56-3603227c89e8","acronym":"ROCKET","url":"https://clinicaltrials.gov/study/NCT02096354","created_at":"2021-01-18T09:40:38.201Z","updated_at":"2024-07-02T16:36:10.444Z","phase":"Phase 2","brief_title":"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02096354 - ROCKET","lead_sponsor":"EpicentRx, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • irinotecan • nibrozetone (RRx-001)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/13/2018","primary_completion_date":" 04/13/2018","study_txt":" Completion: 04/13/2018","study_completion_date":" 04/13/2018","last_update_posted":"2022-05-16"},{"id":"7bec813b-14cc-42a1-bb04-2fb83e17c553","acronym":"","url":"https://clinicaltrials.gov/study/NCT04653142","created_at":"2021-07-24T16:52:37.044Z","updated_at":"2024-07-02T16:36:10.679Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)","source_id_and_acronym":"NCT04653142","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 04/20/2022","primary_completion_date":" 04/20/2022","study_txt":" Completion: 04/20/2022","study_completion_date":" 04/20/2022","last_update_posted":"2022-05-10"}]